retatrutide clinical trial parkinson Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a Top Obesity Clinical Trials |

Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively

10.1371/journal.pone.0095945 111 MasonJ

doi: 10.5314/wjd.v9.i1.1 534 BrodmannTEndoAGueimondeMVinderolaGKneifelWde VosWMet al

10.3748/wjg.v20.i40.14652 [DOI] [PMC free article] [PubMed] [Google Scholar] 7.Mota M, Banini B, Cazanave S, Sanyal A